Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
6(85.7%)
Phase 4
1(14.3%)
7Total
N/A(6)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT04375852Not ApplicableCompleted

Tyrosine Hydroxylase Antibody Levels in Autoimmune Polyglandular Syndrome Type 1 Associated Keratitis

Role: lead

NCT04010110Completed

Hydroxychloroquine Dosing and Toxicity in Ophthalmology Clinics

Role: lead

NCT02794610Not ApplicableUnknown

Ocular Penetration of Topical Tacrolimus Eye Drops

Role: lead

NCT02766855Not ApplicableCompleted

Efficacy of Topical Cysteamine in Nephropathic Cyctinosis

Role: lead

NCT02456025Phase 4Unknown

Topical Tacrolimus in Vernal Keratoconjunctivitis

Role: lead

NCT01958567Not ApplicableCompleted

Optical Coherence Tomography in the Diagnosis of Scleritis and Episcleritis

Role: lead

NCT01905579Not ApplicableCompleted

Correlation Between Aqueous Protein Level and Clinical Grading of Flare and Flaremetry.

Role: lead

NCT02189447Not ApplicableCompleted

Photorefractive Keratectomy and Corneal Cross-linking in Keratoconus

Role: lead

All 8 trials loaded